Publication | Open Access

Investigational Aurora A kinase inhibitor alisertib (MLN8237) as an enteric-coated tablet formulation in non-hematologic malignancies: Phase 1 dose-escalation study

Dose-escalation StudyNon-hematologic MalignanciesEnteric-coated Tablet FormulationMedicineMalignant Blood DisorderPharmacologyPharmacotherapyAnti-cancer AgentOncologyRadiation OncologyCancer Research